|1.||Zhou, Yu-Dong: 1 article (08/2013)|
|2.||Du, Lin: 1 article (08/2013)|
|3.||Nagle, Dale G: 1 article (08/2013)|
|4.||Kelly, Michelle: 1 article (08/2013)|
|5.||Li, Jun: 1 article (08/2013)|
|6.||Zheng, Weili: 1 article (08/2012)|
|7.||Wang, Rui: 1 article (08/2012)|
|8.||Chen, Jinan: 1 article (08/2012)|
|9.||Wang, Zhao: 1 article (08/2012)|
|10.||Jin, Lihua: 1 article (08/2012)|
06/01/1989 - "The PLA2 inhibitors, luffariellolide and aristolochic acid, reduced the edema but only when coinjected with the PLA2. "
01/01/1995 - "PMA-induced ear edema was effectively inhibited by scalaradial, luffariellolide and aristolochic acid (ED50 = 70, 50 and 50 micrograms/ear, respectively) whereas ellagic acid was less effective (ED50 = 230 micrograms/ear). "
|4.||Contact Dermatitis (Eczema, Contact)
|5.||Colonic Neoplasms (Colon Cancer)
08/15/2012 - "Functional characterization further revealed that luffariellolide displays chemotherapeutic potentials for overcoming RA resistance in colon cancer cells, suggesting that luffariellolide may represent a unique template for designing novel non-retinoid compounds with advantages over current RA drugs."
|1.||aristolochic acid I (aristolochic acid)